Differentiated HepaRG cells are cryopreserved at P16 : at D0 or starting D8.
Differentiated HepaRG cells are single-use disposable product that should be destroyed upon conclusion of a study or experiment
Differentiated HepaRG cells are not intended to be expanded or refrozen.
Differentiated HepaRG cells are available under a Limited Use License Agreement (LULA).
Simple commitment of the user to comply to the LULA, no document to execute.
Differentiated HepaRG cells contains 8 million cells per vial and can be used for seeding one 96 well-plate or one 24 well-plate.
The HepaRG™ cell line are required for specific media and additives produced for thawing, plating, culture, maintenance, differentiation, as well as medium.
Use of differentiated HepaRG cells
3D HepaRG SPHEROID CULTURE
For metabolism studies in suspension: Use cells directly after thawing
For metabolism and toxicity studies in monolayer
Toxicity endpoint applications.
Limited License Agreement
HepaRG cells are owned and patented by INSERM and their use is strictly restricted.
Cells must be treated as a single-use disposable product that must be destroyed upon conclusion of a study or experiment.
Propagating, reproducing, cloning, subcloning, or any use of the Cells following the conclusion of a study, are prohibited.
Using the Cells themselves to act as, produce, or manufacture commercial products for sale or intended for sale, is prohibited.
Transfer of the Cells, whether for compensation or not, to (i) anyone who is not employed within the same organization, or (ii) who is not involved in a formally-established Scientific Collaboration with the original recipient of the Cells, is prohibited.
Scientific Collaborator to whom the Cells are transferred should adhere to the aforementioned restrictions.
The original recipient of the Cells should notify Biopredic International of any violation of these restrictions by the Collaborator.
Violations of this Limited Use License will be prosecuted to the fullest extent of the law